Solid Biosciences (SLDB) director Ian Smith granted options and RSUs

Rhea-AI Filing Summary

Solid Biosciences director Ian F. Smith reported multiple equity award transactions. On 01/02/2026, he received a stock option for 18,012 shares of common stock at an exercise price of $5.45 per share and a grant of 13,761 restricted stock units (RSUs). These “Smith Equity Awards” vest in equal quarterly installments over 12 months from the grant date, with full acceleration if the Smith Agreement ends early or there is a change in control of the company.

On 01/06/2026, 4,573 previously granted RSUs fully vested and converted to 4,573 shares of common stock on a one‑for‑one basis. After these transactions, Smith directly held 131,264 shares of Solid Biosciences common stock, along with 18,012 options and 13,761 RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH IAN F

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		M		4,573	A	(1)	131,264	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.45	01/02/2026		A		18,012		(2)	01/02/2036	Common Stock	18,012	$0.00	18,012	D
Restricted Stock Units	(3)	01/02/2026		A		13,761		(2)	(2)	Common Stock	13,761	$0.00	13,761	D
Restricted Stock Units	(1)	01/06/2026		M			4,573	(4)	(4)	Common Stock	4,573	$0.00	0	D

Explanation of Responses:

1. Restricted stock units convert to common stock on a one-for-one basis.

2. The Smith RSUs (as defined in footnote 3) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 2, 2026 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Fourth Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full.

3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs").

4. The restricted stock units were granted on January 6, 2025 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.

	/s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Ian F. Smith report for Solid Biosciences (SLDB)?

Ian F. Smith, a director of Solid Biosciences, reported the grant of a stock option for 18,012 shares at an exercise price of $5.45, a grant of 13,761 RSUs on 01/02/2026, and the vesting and conversion of 4,573 RSUs into common shares on 01/06/2026.

How do the new equity awards to Ian F. Smith at Solid Biosciences vest?

The stock option for 18,012 shares and the 13,761 RSUs granted on 01/02/2026 equal quarterly installments over 12 months, starting three months after the grant date. They fully accelerate if the Smith Agreement ends early or if there is a change in control of Solid Biosciences.

How many Solid Biosciences (SLDB) shares does Ian F. Smith own after these Form 4 transactions?

Following the reported transactions, Ian F. Smith directly owned 131,264 shares of Solid Biosciences common stock, plus 18,012 stock options and 13,761 RSUs.

What happened to the 4,573 restricted stock units reported by Ian F. Smith?

The 4,573 RSUs reported with transaction code M on 01/06/2026 were previously granted on 01/06/2025. They vested in equal quarterly installments over 12 months and then converted one‑for‑one into 4,573 shares of Solid Biosciences common stock.

What does each restricted stock unit (RSU) reported by Ian F. Smith represent?

Each RSU reported by Ian F. Smith represents a contingent right to receive one share of Solid Biosciences common stock, as described in the filing’s footnotes.

Is Ian F. Smith’s ownership in Solid Biosciences direct or through another entity?

The Form 4 indicates that the reported common stock, options, and RSUs are held with direct (D) ownership by Ian F. Smith, with no separate entity listed for indirect ownership.